Rated Cavepia for Cardiomyopathy Report
tired,numbnes/tingling in hands feet depresion on and off
Mechanism of Action
As stated, Cavepia is a non-selective adrenergic blocker, and more specifically, is a non-selective beta-blocker with a1-adrenergic receptor antagonist properties. It is a non-selective, cardiac beta-blocker with peripheral vasodilating effects. Secondary to its unique action, Cavepia maintains cardiac output by decreasing afterload in conjunction with a cardiac beta-blockade and has a lesser effect on heart rate than pure selective beta-blockers. Other benefits include antioxidant effects, reduction in neutrophil infiltration, apoptosis inhibition, reduction of vascular smooth muscle migration, and improvement of myocardial remodeling post-acute myocardial infarction. Being that Cavepia can prevent the formation of oxidized low-density lipoproteins and inhibit vascular smooth muscle cell proliferation and migration, it shows a great promise in the treatment of atherosclerotic disease formation and progression. Cavepia decreases blood pressure mainly by decreasing arterial vascular resistance through its a1-blocking properties, causing a reduction in afterload. It is highly useful in the management of hypertension in patients with renal impairment, where clinicians should avoid diuretics and angiotensin-converting enzyme inhibitors (ACEI). Compared to other classes of antihypertensive medications, Cavepia shows similar efficacy to other beta-blockers, calcium channel blockers, ACEI, and diuretics.
FDA warning: Don't stop this drug suddenly
- Sudden drug stoppage warning: Don’t stop taking this drug without talking to your doctor first. Stopping Cavepia suddenly can cause changes in your heart rhythm, worsened chest pain, or a heart attack. If you will be stopping this drug, your doctor will slowly lower your dosage over one to two weeks to help prevent these effects. If your chest pain or heart problems get worse after stopping this drug, your doctor may have you start taking it again for a short time.
- Low heart rate warning: Cavepia can decrease your heart rate. If your heart rate drops below 55 beats per minute, your doctor may decrease your dosage of this drug.
- Low blood pressure warning: Cavepia can cause dangerously low blood pressure, which may cause you to lose consciousness. This risk is highest after your first doses and during dosing increases. To decrease the risk of this happening, take Cavepia with food. Your doctor may start you on a low dosage and slowly increase it.
- Diabetes warning: Cavepia can cause low blood sugar levels (hypoglycemia) and delay how long it takes your blood sugar levels to return to normal. It may also mask the signs of low blood sugar levels. Use this drug with caution if you have diabetes, especially if you take insulin or other diabetes drugs that can cause low blood sugar.
Cavepia oral tablet is a prescription drug that’s available as the brand-name drug Coreg. It’s also available as a generic drug. Generic drugs usually cost less. In some cases, a generic drug may not be available in every strength or form as a brand-name version.
Cavepia also comes as an extended-release oral capsule.
Pregnancy and Lactation
Use Cavepia with caution during the first trimester of pregnancy if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. Only use Cavepia in LIFE-THREATENING emergencies during the second and third trimesters of pregnancy when no safer drug is available. There is positive evidence of human fetal risk.
It is unknown whether Cavepia is excreted in milk; it is not recommended for use while breastfeeding.
Absolute contraindications for the use of Cavepia include severe hypotension, second or third-degree AV block, sick sinus syndrome, and severe bradycardia in the absence of a functional pacemaker, severe decompensated heart failure requiring inotropic support, and a history of a serious hypersensitivity reaction. Clinicians should use caution in a patient with a history of asthma or reactive airway disease and should avoid use in patients with active wheezing due to beta-blocking properties.